Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
226 Leser
Artikel bewerten:
(0)

Lung Cancer Alliance Praises Congresswoman Donna Christensen (D-VI) for Continued Leadership on Lung Cancer

Brings Attention to High Risk Military During floor debate on Defense Spending with Additional $10.2 million included in House FY12 Defense Appropriations Bill for Lung Cancer Research

WASHINGTON, July 8, 2011 /PRNewswire-USNewswire/ -- Today, Lung Cancer Alliance (LCA) praised Congresswoman Donna Christensen (D-VI) for her continued leadership on lung cancer issues and for bringing the issue to the floor during defense spending debates, for the upcoming fiscal year, in the House of Representatives last night.

Christensen cited the grim statistics on lung cancer, the leading cancer killer in every ethnic group, and its disproportionate impact on veterans whose service has put them at even higher risk.

"As a physician, I know that success against lung cancer requires that we approach lung cancer comprehensively just as we do for other major illnesses," she said.

Nearly one out of every three cancer deaths is due to lung cancer, and despite the fact that no significant progress has been made in reducing its 85% mortality rate, a comprehensive, coordinated plan of action has never been developed.

Christensen, who has been the primary sponsor of lung cancer legislation for the past four years, said: "We owe it to our Nation's heroes to coordinate early screening, treatment, and care, and reduce lung cancer mortality among members of the Armed Forces and our veterans, whose exposure to carcinogens during active duty service is a known contributor to their increased lung cancer risk."

In response, the House Appropriations Committee Ranking Member, Norm Dicks (D-WA), agreed and gave assurances of his commitment to work with the Congresswoman on the issues.

He also noted that an additional $10.2 million for lung cancer was being included in the Department of Defense (DOD) Appropriations package for FY2012, referring to the early detection research programLCA was able to have established within Congressionally Directed Medical Research Program (CDMRP) at DOD in 2009.

If the new infusion of funding is also approved by the Senate, as it was by the House last night, the total amount funneled to researchers through that program to-date will equal $58 million.

LCA President and CEO, Laurie Fenton-Ambrose praised Congresswoman Christensen for her "passionate and persistent leadership" on lung cancer issues.

"Given the sorry state of lung cancer, the underfunding of research, and the stigma and negativity that have been associated with this disease for too long, we need that kind of passionate and persistent leadership to finally bring about a change in federal lung cancer policy, and we are deeply grateful," she said.

Fenton-Ambrose also praised Congressman Dicks for his support for lung cancer research funding and his commitment for a coordinated plan of action.

"Now that we have had scientific validation that CT screening those at high risk for lung cancer can dramatically reduce lung cancer deaths, we must move forward aggressively to integrate early detection, smoking cessation, increased research into non-tobacco related lung cancer and better disease management," she said.

For more information about the Lung Cancer Mortality Reduction Act please visit www.lungcanceralliance.org.

Lung Cancer Alliance is the only national non-profit organization dedicated exclusively to patient support and advocacy for those living with or at risk for lung cancer. Lung Cancer Alliance is committed to leading the movement to reverse decades of stigma and neglect by empowering those with or at risk for the disease, elevating awareness and changing health policy.

Follow Lung Cancer Alliance on Facebook: www.facebook.com/lungcanceralliance

Media Contact:
Kay Cofrancesco
Kay@lungcanceralliance.org
202-463-2080

SOURCE Lung Cancer Alliance

© 2011 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.